In an ongoing trial of people on failing antiretroviral regimens, the injectable PRO 140 reduced viral load considerably.

The Food and Drug Administration approves antibody treatment Trogarzo for multidrug-resistant HIV.

However, two similar cases have been reported in Australia.

U.K. public health officials have expressed great concern over this latest sign of evolution of the sexually transmitted infection.

An analysis of the Seattle area HIV population sought to determine the prevalence of virus resistant to both drugs in Truvada.

After a gay man tested HIV positive, a test of his hair indicated he’d adhered well to PrEP—but did he contract a drug-resistant strain?

The intravenous medication, which should be used with standard antiretrovirals, has a wholesale acquisition cost of $118,000 per year.

One injection of the cloned antibody significantly reduced participants’ viral load in a recent advanced trial.

Chinese researchers have added their voices to the global chorus warning that the STI is showing increasing signs of antibiotic resistance.

The high proportion of individuals starting treatment with drug resistance already warrants changing the recommended first-line therapy.